CureVac N.V. Form 6-K (May 28, 2021)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of May, 2021, Commission File Number 001-39446. It states that on May 28, 2021 the company issued a press release announcing that the Independent Data Safety Monitoring Board has confirmed that the pivotal Phase 2b/3 study, called HERALD, for its first-generation COVID-19 vaccine candidate, CVnCoV, has passed an interim analysis. It adds that further data is required to prove efficacy with statistical significance, so the study will continue. The press release is listed as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of May, 2021

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | X | Form 40-F

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | No | X

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | No | X

On May 28, 2021, CureVac N.V. (the “Company”) issued a
press release announcing that the Independent Data Safety Monitoring Board has confirmed that the pivotal Phase 2b/3 study, called HERALD,
for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed an interim analysis. As further data is required to
prove efficacy with statistical significance, the study will continue.

The information in this Form 6-K (including Exhibit 99.1) shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: May 28, 2021

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated May 28, 2021.

File and source

File

SEC_CVAC_6-K_filed2021-05-28_0001104659-21-074210.htm

Size

13,055 bytes

SHA-256

a91ef01cab1311141d65d64c01d2b9cb3c6d5f12fc967d68bfbf2eb06c22d9f4

Our copy

SEC_CVAC_6-K_filed2021-05-28_0001104659-21-074210.htm

Original

www.sec.gov